Napsin A is a Specific Marker for Ovarian Clear Cell Adenocarcinoma

Overview

Journal Mod Pathol

Specialty Pathology

Date 2014 Apr 12

PMID 24721826

Citations 26

Authors

Yoriko Yamashita

Tetsuro Nagasaka

Aya Naiki-Ito

Shinya Sato

Shugo Suzuki

Shinya Toyokuni

Masafumi Ito

Satoru Takahashi

Affiliations

Soon will be listed here.

Abstract

Ovarian clear cell adenocarcinoma has a relatively poor prognosis among the ovarian cancer subtypes because of its high chemoresistance. Differential diagnosis of clear cell adenocarcinoma from other ovarian surface epithelial tumors is important for its treatment. Napsin A is a known diagnostic marker for lung adenocarcinoma, and expression of napsin A is reported in a certain portion of thyroid and renal carcinomas. However, napsin A expression in ovarian surface epithelial tumors has not previously been examined. In this study, immunohistochemical analysis revealed that in 71 of 86 ovarian clear cell adenocarcinoma patients (83%) and all of the 13 patients with ovarian clear cell adenofibroma, positive napsin A staining was evident. No expression was observed in 30 serous adenocarcinomas, 11 serous adenomas or borderline tumors, 19 endometrioid adenocarcinomas, 22 mucinous adenomas or borderline tumors, 10 mucinous adenocarcinomas, or 3 yolk sac tumors of the ovary. Furthermore, expression of napsin A was not observed in the normal surface epithelium of the ovary, epithelia of the fallopian tubes, squamous epithelium, endocervical epithelium, or the endometrium of the uterus. Therefore, we propose that napsin A is another sensitive and specific marker for distinguishing ovarian clear cell tumors (especially adenocarcinomas) from other ovarian tumors.

Citing Articles

Utilization of immunohistochemistry in gynecologic tumors: An expert review.

Katcher A, Greenman M, Roychoudhury S, Goldberg G Gynecol Oncol Rep. 2024; 56:101550.

PMID: 39717157 PMC: 11664289. DOI: 10.1016/j.gore.2024.101550.

Unraveling disulfidptosis for prognostic modeling and personalized treatment strategies in lung adenocarcinoma.

Xu X, Zhang B, Zhang J, Ma H Future Sci OA. 2024; 10(1):2432211.

PMID: 39587729 PMC: 11601057. DOI: 10.1080/20565623.2024.2432211.

Non-small cell lung carcinoma with clear cell features: a clinicopathologic, immunohistochemical, and molecular study of 31 cases.

Suster D, Ronen N, Mejbel H, Harada S, Mackinnon A, Suster S Virchows Arch. 2024; 485(1):83-96.

PMID: 38814477 DOI: 10.1007/s00428-024-03833-5.

Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.

Cheng Y, Li Q, Sun G, Li T, Zou Y, Ye H Sci Rep. 2024; 14(1):9757.

PMID: 38684875 PMC: 11058243. DOI: 10.1038/s41598-024-60544-2.

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.

Thorel L, Morice P, Paysant H, Florent R, Babin G, Thomine C J Exp Clin Cancer Res. 2023; 42(1):260.

PMID: 37803448 PMC: 10559504. DOI: 10.1186/s13046-023-02809-8.

References

Warth A, Muley T, Herpel E, Meister M, Herth F, Schirmacher P . Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology. 2012; 61(6):1017-25. DOI: 10.1111/j.1365-2559.2012.04308.x. View

Ueno T, Linder S, Elmberger G . Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003; 88(8):1229-33. PMC: 2747556. DOI: 10.1038/sj.bjc.6600879. View

Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T . Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000; 88(11):2584-9. View

Toyama A, Suzuki A, Shimada T, Aoki C, Aoki Y, Umino Y . Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Sci. 2012; 103(4):747-55. PMC: 7659196. DOI: 10.1111/j.1349-7006.2012.02224.x. View

Mori K, Shimizu H, Konno A, Iwanaga T . Immunohistochemical localization of napsin and its potential role in protein catabolism in renal proximal tubules. Arch Histol Cytol. 2002; 65(4):359-68. DOI: 10.1679/aohc.65.359. View

Kennedy A, Biscotti C, HART W, Webster K . Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989; 32(3):342-9. DOI: 10.1016/0090-8258(89)90637-9. View

Ueno T, Linder S, Na C, Rice W, Johansson J, Weaver T . Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem. 2004; 279(16):16178-84. DOI: 10.1074/jbc.M312029200. View

Whithaus K, Fukuoka J, Prihoda T, Jagirdar J . Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012; 136(2):155-62. DOI: 10.5858/arpa.2011-0232-OA. View

Bishop J, Sharma R, Illei P . Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2009; 41(1):20-5. DOI: 10.1016/j.humpath.2009.06.014. View

10.

Silva E, Young R . Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol. 2007; 31(8):1203-8. DOI: 10.1097/PAS.0b013e3180339ed7. View

11.

Kato N, Sasou S, Motoyama T . Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2005; 19(1):83-9. DOI: 10.1038/modpathol.3800492. View

12.

Cetin A, Bahat Z, Cilesiz P, Cikesiz P, Demirbag N, Yavuz E . Ovarian clear cell adenocarcinoma producing alpha-fetoprotein: case report. Eur J Gynaecol Oncol. 2007; 28(3):241-4. View

13.

DeLair D, Oliva E, Kobel M, Macias A, Gilks C, Soslow R . Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol. 2010; 35(1):36-44. DOI: 10.1097/PAS.0b013e3181ff400e. View

14.

Sangoi A, Soslow R, Teng N, Longacre T . Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential. Am J Surg Pathol. 2008; 32(2):269-74. DOI: 10.1097/PAS.0b013e31814fa9b0. View

15.

Nolan L, Heatley M . The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol. 2001; 20(2):155-9. DOI: 10.1097/00004347-200104000-00007. View

16.

Fadare O, Liang S . Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012; 20(6):580-7. DOI: 10.1097/PAI.0b013e31824973d1. View

17.

Brasch F, Ochs M, Kahne T, Guttentag S, Schauer-Vukasinovic V, Derrick M . Involvement of napsin A in the C- and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung. J Biol Chem. 2003; 278(49):49006-14. DOI: 10.1074/jbc.M306844200. View

18.

Tatnell P, Powell D, Hill J, Smith T, Tew D, Kay J . Napsins: new human aspartic proteinases. Distinction between two closely related genes. FEBS Lett. 1999; 441(1):43-8. DOI: 10.1016/s0014-5793(98)01522-1. View

19.

Hirano T, Gong Y, Yoshida K, Kato Y, Yashima K, Maeda M . Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer. 2003; 41(2):155-62. DOI: 10.1016/s0169-5002(03)00194-6. View

20.

Bur D, Kling D, Gruninger F, Giller T . Human napsin A: expression, immunochemical detection, and tissue localization. FEBS Lett. 1999; 462(1-2):135-9. DOI: 10.1016/s0014-5793(99)01458-1. View